Testosterone Therapy for the Treatment of Age-Related Hypogonadism: Risks with Uncertain Benefits

Testosterone replacement therapy has been approved in the United States since the 1950s for men with “classical” hypogonadism. These men have specific and well-recognized hypothalamic, pituitary, or testicular conditions leading to deficient or absent endogenous testosterone. A more controversial tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Christine P., Hirsch, Mark, Kaul, Suresh, Woods, Corinne, Joffe, Hylton V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2021
Materias:
Point
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142681/
https://www.ncbi.nlm.nih.gov/pubmed/34041509
http://dx.doi.org/10.1089/andro.2020.0018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142681/
https://www.ncbi.nlm.nih.gov/pubmed/34041509
http://dx.doi.org/10.1089/andro.2020.0018

Ejemplares similares